1. Introduction {#sec1}
===============

For decades, proteins and peptides with small size have been widely used in number of diseases.^[@ref1]−[@ref3]^ Despite high therapeutic potency, however, their small size was known to undergo a fast renal clearance and poor biodistribution profile, which often result in frequent dosing and low therapeutic efficacy.^[@ref4],[@ref5]^ In an efforts to overcome poor pharmacokinetic profiles of small-sized therapeutic proteins, various strategies have been suggested.^[@ref6],[@ref7]^ Either serum albumin or Fc of immunoglobulin was conjugated to therapeutic proteins through genetic fusion or chemical methods for the FcRn-mediated recycling.^[@ref8]−[@ref14]^ PEGylation, biotinylation, and multimerization are also widely used to increase the hydrodynamic radius of such proteins.^[@ref15]−[@ref22]^ A natural binder of serum albumin, fatty acid, was conjugated to a glucagon-like peptide-1 (GLP-1) analogue using a chemically synthesized short-length peptide, significantly extending its blood half-life.^[@ref23]−[@ref25]^ Some factors affecting the biological activity and half-life of a therapeutic protein in fatty acid conjugation were investigated.^[@ref26]−[@ref28]^ Even though such methods have been widely employed, some shortcomings still remain to be improved. Chemical conjugation or multimerization can lead to heterogeneous products, and the resulting proteins often undergo a steric hindrance for a binding to their target molecules.^[@ref15],[@ref21]^ Genetic fusion with serum proteins or Fc is expensive and complicated because of its requirement of mammalian expression system.^[@ref29],[@ref30]^ Furthermore, genetic fusion or chemical conjugation with exogenous proteins often causes unwanted immunogenicity.^[@ref31]−[@ref33]^ In particular, chemical conjugation methods tend to need complex chemical reaction steps, which result in high heterogeneity and a low yield.

Herein, we show that site-specific lipidation of a protein binder with low molecular weight through incorporation of an unnatural amino acid significantly enhances the blood circulation time and consequently the antitumor activity *in vivo*. As a proof-of concept, a previously developed human IL-6 targeting protein binder (∼31 kDa) was employed.^[@ref34]^ A specific site of the protein binder with highest accessibility was selected and incorporated with an unnatural amino acid, 4-azido-[l]{.smallcaps}-phenylalanine, followed by conjugation with palmitic acid through copper-free click chemistry ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). The property of the lipidated protein binder was investigated in terms of binding ability for serum albumin and human IL-6. The utility of our approach was shown by a significantly prolonged half-life and enhanced tumor suppression in the xenograft mice model. Details are reported herein.

![Site-specific lipidation of a human IL6-targeting repebody. (A) Structure of the repebody (PDB ID: 4J4L) and a lipidation site on its convex region indicated by a blue color. (B) Chemical structure of 4-azido-[l]{.smallcaps}-phenylalanine. (C) Chemical structure of palmitic acid. DBCO-palmitic acid was used for conjugation with 4-azido-[l]{.smallcaps}-phenylalanine through copper-free click chemistry. Chemical structures were drawn by using ChemSketch. (D) Schematic diagram of site-specifically lipidated repebody.](ao0c02555_0001){#fig1}

2. Results and Discussion {#sec2}
=========================

2.1. Construction of an Unnatural Amino Acid-Incorporated Repebody {#sec2.1}
------------------------------------------------------------------

As a model, a previously developed human IL-6-specific repebody (31 kDa) was employed. To select a site on the repebody for fatty acid conjugation, a relative surface accessibility was assessed for each amino acid residue based on the repebody structure (PDB ID: 4J4L) using a web server.^[@ref35]^ As a result, aspartic acid at position 126 on the convex region was selected ([Figure S1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c02555/suppl_file/ao0c02555_si_001.pdf)), and its codon was mutated to TAG ([Figure S2](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c02555/suppl_file/ao0c02555_si_001.pdf)). With an amber codon-recognizing tRNA synthetase, 4-azido-[l]{.smallcaps}-phenylalanine (AzF) was incorporated into the position 126 on the repebody. The resulting repebody (AzF-Rb) was expressed in Origami B (DE3) as a soluble form and further purified for high homogeneity ([Figure S3](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c02555/suppl_file/ao0c02555_si_001.pdf)).

For efficient conjugation of a fatty acid to the human IL-6-specific repebody, the azido group of 4-azido-[l]{.smallcaps}-phenylalanine on the repebody should be accessible and functionally active. We checked the functionality of azido group on the repebody by conjugation of various molecules. PEG (MW 5 kDa) was tested, and PEGylation was confirmed by a shift in sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis ([Figure S4](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c02555/suppl_file/ao0c02555_si_001.pdf)). When DBCO-modified Cy3 dye was conjugated, a distinct fluorescence signal was detected by gel imaging ([Figure S5](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c02555/suppl_file/ao0c02555_si_001.pdf)). In addition, biotin was treated with the repebody, and biotinylated repebody was detected by HRP-conjugated streptavidin ([Figure S6](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c02555/suppl_file/ao0c02555_si_001.pdf)). These results indicate that the azido group of 4-azido-[l]{.smallcaps}-phenylalanine incorporated into the repebody is accessible and functionally active to be conjugated with PEG, fluorescent dye, and biotin.

2.2. Site-Specific Conjugation of a Fatty Acid {#sec2.2}
----------------------------------------------

Fatty acid is known to bind to a serum albumin through hydrophobic interaction.^[@ref36]−[@ref40]^ To extend the blood circulation time of a repebody, we conjugated palmitic acid (14-carbon length) to 4-azido-[l]{.smallcaps}-phenylalanine on the repebody through copper-free click chemistry. The resulting repebody (Pal-Rb) showed a single large peak by size exclusion chromatography ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A) and high purity with expected molecular weight (31.5 kDa) by SDS-PAGE ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B). The Pal-Rb showed a distinct size shift in SDS-PAGE compared to the 4-azido-[l]{.smallcaps}-phenylalanine-incorporated repebody (AzF-Rb). These results indicate a site-specific conjugation of palmitic acid and homogeneity of the lipidated repebody.

![Purification and analysis of a palmitic acid-conjugated repebody. (A) Elution profile of a palmitic acid-conjugated repebody (Pal-Rb) by size exclusion chromatography. (B) SDS-PAGE analysis of Pal-Rb. The Pal-Rb band was shifted compared to the 4-azido-[l]{.smallcaps}-phenylalanine-incorporated repebody (AzF-Rb).](ao0c02555_0002){#fig2}

2.3. Binding Characteristics of a Lipidated Repebody {#sec2.3}
----------------------------------------------------

We checked the binding capacity of Pal-Rb for a target protein, human IL-6, using direct ELISA. It is desirable that conjugation of a fatty acid has no effect on the binding ability of the repebody. A 96-well plate was coated with human IL-6, followed by addition of a serially diluted Pal-Rb or wild-type repebody (WT-Rb). Amount of target-bound repebody was detected by biotin-conjugated antirepebody antibody and HRP-labeled streptavidin. As a result, Pal-Rb showed a 4-fold decreased binding affinity compared to WT-Rb ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A), and this seems to be because of a steric hindrance caused by a conjugated-palmitic acid.

![Binding profiles of a palmitic acid-conjugated repebody (Pal-Rb) against human IL-6 and MSA. (A) Binding profile of Pal-Rb against human IL-6. A serially diluted Pal-Rb was added to a human IL-6-coated 96-well plate, and the amount of bound Pal-Rb was measured by direct ELISA. As a control, wild-type human IL-6-specific repebody (WT-Rb) was used. (B) Binding profile of Pal-Rb against MSA. A serially diluted Pal-Rb was added to an MSA-coated 96-well plate, and the amount of bound Pal-Rb was measured by ELISA. WT-Rb and AzF-Rb were used as controls. Error bars describe mean ± standard deviation (*n* = 3).](ao0c02555_0003){#fig3}

We next tested whether a repebody-conjugated palmitic acid has a binding capacity for mouse serum albumin (MSA). Pal-Rb, AzF-Rb, or WT-Rb was serially diluted and added to a 96-well plate, which had been coated with MSA, followed by analysis of the bound repebody ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B). Pal-Rb was shown to have a distinct binding ability for MSA, whereas both WT-Rb and AzF-Rb displayed a negligible binding capacity. These results indicate that site-specifically conjugated palmitic acid can bind to a MSA and therefore might lead to longer circulation time in blood by reducing renal clearance and FcRn-mediated recycle. A slight decrease in binding affinity of a Pal-Rb is expected to be compensated by its prolonged blood circulation time in terms of therapeutic efficacy.

2.4. Pharmacokinetic Profile of a Lipidated Repebody {#sec2.4}
----------------------------------------------------

We investigated the pharmacokinetic profile of a palmitic acid-conjugated repebody (Pal-Rb) in mice ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}). Each construct was injected intravenously, and the serum levels of repebody were monitored. The distribution half-life was 4.2 h, and elimination half-life was 10.7 h for Pal-Rb. In contrast, initial half-life was estimated to be 20 min for WT-Rb. Terminal half-life was not able to be calculated because of its fast clearance. The AUC of Pal-Rb was about 747%·h, which is 4.2-fold higher than WT-Rb. This result demonstrates that conjugation of palmitic acid significantly improved the pharmacokinetic property of the repebody (*p* \< 0.05), leading to an increased bioavailability compared to WT-Rb. Therefore, our present approach can be widely applied to small-sized proteins and peptides that suffer from short blood circulation time.

![Pharmacokinetic profile of a palmitic acid-conjugated repebody in mice. A palmitic acid-conjugated repebody (Pal-Rb) was intravenously injected (*n* = 5 per each group). The levels of Pal-Rb inside blood plasma were determined by sandwich ELISA. WT-Rb was used as a control. Pharmacokinetic parameters for each constructs were estimated based on the profile. Error bars describe mean ± standard deviation (\**p* \< 0.05).](ao0c02555_0004){#fig4}

2.5. Antitumor Activity of a Palmitic Acid-Conjugated Repebody *In Vivo* {#sec2.5}
------------------------------------------------------------------------

Based on the significant enhancement in the pharmacokinetic profile of Pal-Rb, we tested its therapeutic efficacy in the tumor xenograft mice model. IL-6 is known to play a crucial role in cancer cell proliferation through stimulation of signal transducer and activator of transcription 3 (STAT3)-signaling pathway.^[@ref41]−[@ref43]^ Thus, the IL-6-specific repebody is expected to inhibit the STAT3-signaling pathway, suppressing the growth of tumor cells. H1650 cells, which are nonsmall cell lung cancer cell line, were used. Pal-Rb (10 mg/kg) was injected on every 3 days intravenously ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}A). As the controls, WT-Rb and PBS were used. As a result, Pal-Rb suppressed the tumor growth level significantly when compared with controls ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}B,C). The tumor size remained around 200 mm^3^ until 27 days when Pal-Rb was administered (*p* \< 0.01), whereas tumor continued to grow over 600 mm^3^ when WT-Rb and PBS were injected. The body weight change was not significant for all three groups ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}D). Furthermore, the factors of hepatotoxicity, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were insignificant between all three groups. In addition, nephrotoxicity factor creatine was very low for all three groups, and blood urea nitrogen (BUN) levels were estimated to be insignificant between the groups after 27 days ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}E--G), implying negligible toxicity on both the liver and kidney. These results indicate that site-specific lipidation is effective for enhancing the antitumor activity of small-sized protein therapeutics through prolonged blood circulation time and increased bioavailability.

![Antitumor activity of a palmitic acid-conjugated repebody in H1650 tumor xenograft mice. (A) Experimental schedule for the assessment of tumor growth level when injected with Pal-Rb. (B,C) Effect of Pal-Rb on the tumor growth in xenograft mice. Pal-Rb was injected intravenously (10 mg/kg, *n* = 5 for each group), and tumor growth was monitored in every 3 days for 27 days. WT-Rb and PBS were used as controls. Pal-Rb resulted in a significant suppression of tumor growth compared to WT-Rb (\*\**p* \< 0.01). Error bars describe mean ± standard deviation. (D) Body weight changes of mice injected with Pal-Rb. The body weight change was monitored for 27 days. (E) Hepatotoxicity of Pal-Rb. Blood was analyzed for aspartate aminotransferase (ALT) and alanine aminotransferase (AST) levels at day 27. (F,G) Nephrotoxicity of Pal-Rb. Blood was analyzed for creatine and BUN levels at day 27. Error bars describe mean ± standard deviation.](ao0c02555_0005){#fig5}

3. Conclusions {#sec3}
==============

We have showed that site-specific lipidation is effective for elongating the blood circulation time and consequently enhancing the antitumor activity of the human IL-6-targeting repebody. A palmitic acid conjugated in repebody showed a binding capacity for a MSA, extending the blood circulation time up to 10.7 h, whereas WT-Rb had a shorter half-life of 20 min. The prolonged blood half-life and enhanced bioavailability of the lipidated repebody led to a significant enhancement in tumor suppression in the xenograft mice model, even though its binding affinity for human IL-6 was decreased by around 4-fold. It is interesting to note that conjugation of a palmitic acid had negligible side effects on mice. These results show that the current method can be effective to elongate the circulation time in blood and increase the bioavailability of proteins with low molecular weight and therefore lead to enhancement of their therapeutic effect.

4. Experimental Section {#sec4}
=======================

4.1. Materials {#sec4.1}
--------------

For cloning, the protein expression vector pET21a of Novagen (Madison, WI, USA), NdeI, XhoI restriction enzymes, and T4 DNA Ligase of Takara Bio (Shiga, Japan) was used. For incorporation of 4-azido-[l]{.smallcaps}-phenylalanine, the pEVOL-pAzF plasmid was purchased from Addgene (Watertown, MA, USA). 4-Azido-[l]{.smallcaps}-phenylalanine was from Bachem (Bubendorf, Switzerland) and Chem-Impex International (Wood Dale, IL, USA). DBCO-amine and NHS--palmitic acid were manufactured by Sigma-Aldrich (St. Louis, MO, USA). DBCO-mPEG (5 kDa), DBCO-Cy3, and Dde-Biotin-DBCO were purchased from Click Chemistry Tools (Scottsdale, AZ, USA). LB media, ampicillin, and kanamycin were supplied by Duchefa Biochemie (Haarlem, The Netherlands). Tetracycline and streptomycin were purchased from Sigma-Aldrich. Origami B (DE3) competent cells were provided by EMD Millipore (Burlington, MA, USA). Isopropyl β-[d]{.smallcaps}-1-thiogalactopyranoside (IPTG) used for induction of repebody, and human IL-6 expression was supplied by LPS Solution (Daejeon, Korea). Nickel--nitrilotriacetic acid (Ni--NTA) agarose resin for the purification of his-tagged proteins was supplied by Qiagen (Hilden, Germany), and Sephadex G-25 in PD-10 Desalting column, HiLoad Superdex 75 16/600 column, and Superdex 200 Increase 10/300 column were purchased from GE Healthcare (Uppsala, Sweden). For binding property assessments, Maxibinding 96-well immunoplates were purchased from SPL Life Sciences (Seoul, Korea). MSA and bovine serum albumin (BSA) were purchased from Equitech-Bio (Kerrville, TX, USA) and GenDEPOT (Katy, TX, USA), respectively. All other reagents purchased were of analytical grade and used as received.

4.2. Incorporation of an Unnatural Amino Acid and Protein Expression {#sec4.2}
--------------------------------------------------------------------

For a site-specific conjugate of a fatty acid, an amino acid residue on the convex region of the human IL-6-specific repebody with highest surface accessibility was selected by analyzing the amino acid sequence using a web server,^[@ref35]^ and its codon was changed to an amber codon (TAG). The mutated repebody gene was cloned into pET21a vector, and electrocompetent cells were generated using Origami (DE3) *Escherichia coli*. Additionally, the pEVOL-pAzF plasmid was inserted by electro-transformation as described elsewhere.^[@ref44]^ A single colony was seeded in a 10 mL of LB medium containing antibiotics (ampicillin, kanamycin, tetracycline, and streptomycin) and grown overnight at 37 °C. Next day, cells were grown in 1 L of LB medium containing the antibiotics as above and grown at 37 °C until OD~600~ reached 0.8. Isopropyl-*b*-[d]{.smallcaps}-thiogalactopyranoside (IPTG) and 4-azido-[l]{.smallcaps}-phenylalanine (AzF) were added at 1 mM for induction of protein expression and incorporation of AzF, respectively, and incubated for additional 2 days at 30 °C. Cells were harvested by centrifugation at 8000 rpm for 20 min, and 20 mM Tris-HCl (pH 8.0) buffer containing 150 mM NaCl and 10 mM imidazole was added to resuspend cell pellets. Cells were sonicated, and debris was separated by centrifugation at 16,000 rpm for 1 h at 4 °C. Supernatants were purified with the Ni--NTA agarose resin column. Unbound proteins were removed with 20 mM Tris (pH 8.0), 150 mM NaCl, and 20 mM imidazole. Bound proteins were detached from NI--NTA agarose resin using 20 mM Tris (pH 8.0), 150 mM NaCl, and 250 mM imidazole. Eluted proteins were subjected to size exclusion chromatography (HiLoad Superdex 75 16/600). The human IL-6-specific repebody and human IL-6 protein were expressed and purified using the same method in our previous work.^[@ref34]^

4.3. Confirmation of 4-Azido-[l]{.smallcaps}-phenylalanine Incorporation {#sec4.3}
------------------------------------------------------------------------

Incorporation of 4-azido-[l]{.smallcaps}-phenylalanine into the human IL-6-specific repebody was confirmed by PEGylation, Cy3 labeling, and biotinylation. The purified human IL-6-specific repebody with incorporated 4-azido-[l]{.smallcaps}-phenylalanine was reacted with DBCO-mPEG (5 kDa), DBCO-Cy3, and Dde-Biotin-DBCO, respectively, at the molar ratio of 1:10 at room temperature for 24 h. Purification was conducted using the Superdex 200 Increase 10/300 column. PEGylation was checked by a size shift using SDS-PAGE analysis. The Cy3-labeled repebody was subjected to SDS-PAGE, and the fluorescence was detected by a gel image analyzer (Azure C600, Azure Biosystems, Dublin, CA, USA). The biotinylated repebody was analyzed by ELISA using the human IL-6-coated plate and HRP Streptavidin (BioLegend, San Diego, CA, USA).

4.4. Conjugation of a Fatty Acid {#sec4.4}
--------------------------------

Site-specific conjugation of palmitic acid with 4-azido-[l]{.smallcaps}-phenylalanine on the repebody was carried out by copper-free click chemistry as described elsewhere.^[@ref27]^ Briefly, DBCO-amine and NHS--palmitic acid were dissolved in dimethyl sulfoxide and mixed at the molar ratio of 1:5 with 0.1% deoxycholic acid (Sigma-Aldrich) in 1 mL of 1× DPBS (Welgene, Seoul, Korea), and amine reaction was conducted for 24 h at 37 °C. On the following day, remaining NHS--palmitic acid was quenched by adding 200 μL of 1 M Tris (pH 9.0). Following incubation at 37 °C for 2 h, 1 mL of DBCO-functionalized palmitic acid was added to 4-azido-[l]{.smallcaps}-phenylalanine incorporated human IL-6-specific repebody purified in 1× DPBS and incubated at room temperature for 12 h without exposure to light for cooper-free click chemistry reaction. Residual DBCO-palmitic acid was removed by the PD-10 desalting column using Sephadex G-25 and subjected to size exclusion chromatography with the Superdex 75 column. The NanoDrop 2000c spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) was used to measure the concentration of all the expressed proteins with appropriate extinction coefficients ([Table S1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c02555/suppl_file/ao0c02555_si_001.pdf)). SDS-PAGE results were analyzed by the Gel Doc EZ Imager (Bio-Rad, Hercules, CA, USA).

4.5. Binding Ability Assessment {#sec4.5}
-------------------------------

Binding affinity of a repebody against human IL-6 and MSA was tested using ELISA as in our previous work.^[@ref16]^ Briefly, a 96-well plate coated with human IL-6 or MSA (10 μg/mL) was prepared at 4 °C overnight. Wells were blocked by blocking buffer for 1 h at room temperature. PBST-BSA (PBS pH 7.4, 0.05% Tween 20, 1% BSA) was used as the blocking buffer for human IL-6 binding test. A chemical blocker SuperBlock (T20) PBS (Thermo Scientific, Waltham, MA, USA) was used in case of binding test for MSA. Palmitic acid-conjugated repebody (Pal-Rb), 4-azido-[l]{.smallcaps}-phenylalanine-incorporated repebody (AzF-Rb), and WT-Rb were serially diluted by 3-fold with a blocking buffer starting from 1 μM. Each protein (100 μL) was added into well. Target-bound repebody was detected using biotinylated antirepebody antibody (Abclon, Seoul, Korea) with HRP-conjugated streptavidin diluted in blocking buffer. The signal was generated by adding 3,3′,5,5′-tetramethylbenzidien (TMB, Sigma-Aldrich). Absorbance (450 nm) was analyzed after the addition of 1 N H~2~SO~4~ by using the microplate reader (Infinite M200, Tecan GmbH, Crailsheim, Germany). PBST (PBS pH 7.4, 0.05% Tween 20) was used to wash the wells five times between each step, and experiment was conducted in triplicate.

4.6. Pharmacokinetics {#sec4.6}
---------------------

The pharmacokinetic profile of a palmitic acid-conjugated repebody in mice was analyzed as in our previous work.^[@ref45]^ Briefly, Balb/c male mice of 4 weeks old (Orient Bio, Inc., Gwangju, Korea) were intravenously injected either with a Pal-Rb or WT-Rb (10 mg/kg, 100 μL). Whole blood was collected in predetermined time points postinjection (*n* = 5; 0.05, 0.5, 1, 2, 4, 6, 12 and 24 h). After separation of blood plasma by centrifugation, each sample was subjected to sandwich ELISA. Repebody in blood plasma was captured using antirepebody antibody, detected with biotinylated antirepebody antibody, and streptavidin--HRP conjugate prepared in SuperBlock T20 (PBS) blocking buffer. The signal was generated for 1 min after adding the TMB substrate, and 1 N H~2~SO~4~ was added. PBST (PBS pH 7.4, 0.05% Tween 20) was used to wash the wells five times between each step. The value at 3 min was set to 100% for relative comparison of serum concentration. The experiment was reviewed and approved by the IACUC of KAIST (approval no. KA2017-29)

4.7. Antitumor Activity in the Xenograft Mouse Model {#sec4.7}
----------------------------------------------------

### 4.7.1. Animal and Tumor Cell for Xenograft {#sec4.7.1}

The H1650 cell (ATCC, Manassas, VA, USA), which is a nonsmall cell lung cancer cell line, was cultured with RPMI 1640 media containing 10% fetal bovine serum and 100 U/mL penicillin/streptomycin (Capricorn Scientific, Ebsdorfergrund, Germany) and incubated in 37 °C, 5% CO~2~ chamber. Female BALB/c nude mice of five-week-old were provided by Orient Bio, Inc. H1650 cancer cells were injected into mice subcutaneously through the right lateral flank. Total 5 × 10^6^ cells were subcutaneously injected into mice in a mixture with 100 μL of Matrigel Matrix (Corning Inc., Corning, NY, USA) and incubated until approximately 100 mm^3^ of tumor volume was reached. All animals were caged in standard and controlled conditions. The experiment was reviewed and approved by the IACUC of KAERI (approval no. KAERI-IACUC-2019-015).

### 4.7.2. Antitumor Activity {#sec4.7.2}

Pal-Rb, WT-Rb, or PBS (10 mg/kg, 100 μL, *n* = 5 per group) was intravenously injected into xenograft mice with an interval of 3 days when the volume of the tumor grew until approximately 100 mm^3^. The growth of tumor and body weight were monitored once every 3 days for 27 days. On each day, width and length of the tumor were measured using a caliper. The following formula was used to evaluate the tumor volume: width^2^ × length × 0.5. At 27 days postinjection, all mice were euthanized, and tissues were analyzed.

### 4.7.3. *In Vivo* Hepatic and Renal Toxicity {#sec4.7.3}

The blood plasma was separated by centrifugation at 3000 rpm for 20 min at 4 °C. Blood levels of alanine transaminases (ALTs) and aspartate transaminases (ASTs) were analyzed for hepatic toxicity. In case of renal toxicity, blood was analyzed for creatine and BUN levels. The toxicity parameters were detected by Fuji Dri-Chem NX 7000i (Fuji photo Film Co., Ltd., Tokyo, Japan).

4.8. Statistical Analysis {#sec4.8}
-------------------------

Error bars describe mean ± standard deviation. One-way analysis of variance was used to compare individual samples. Tukey's multiple comparison test was used for intergroup comparisons. When the *p* value was less than 0.05 (*p* \< 0.05), the results were described as statistically significant. Statistical analysis was conducted with Prism 8 (GraphPad Software, San Diego, CA, USA).

The Supporting Information is available free of charge at [https://pubs.acs.org/doi/10.1021/acsomega.0c02555](https://pubs.acs.org/doi/10.1021/acsomega.0c02555?goto=supporting-info).Analysis of repebody residues for site-specific lipidation, purification of 4-azido-[l]{.smallcaps}-phenylalanine incorporated repebody, confirmation of 4-azido-[l]{.smallcaps}-phenylalanine incorporation in repebody, and parameters for measurement of protein concentrations ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c02555/suppl_file/ao0c02555_si_001.pdf))
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